Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.46 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12924143 | 0.92 | CA14 (0.47) | CA14SSTR4HDAC6HDAC1HDAC2 | |
| SCHEMBL12924141 | 0.90 | CA14 (0.46) | CA14SSTR4HDAC6HDAC1HDAC2 | |
| SCHEMBL505669 | 0.90 | CA14 (0.46) | CA14SSTR4HDAC6HDAC1HDAC2 | |
| SCHEMBL503444 | 0.90 | CA14 (0.53) | CA14SSTR4HDAC6HDAC1HDAC2 | |
| SCHEMBL24387518 | 0.89 | CA14 (0.51) | CA14SSTR4HDAC6HDAC1HDAC2 | |
| SCHEMBL22123313 | 0.89 | CA14 (0.51) | CA14SSTR4HDAC6HDAC1HDAC2 | |
| SCHEMBL28584989 | 0.88 | CA14 (0.51) | CA14SSTR4HDAC6HDAC1HDAC2 | |
| SCHEMBL745378 | 0.88 | CA14 (0.51) | CA14SSTR4HDAC6HDAC1HDAC2 | |
| SCHEMBL26086305 | 0.88 | CA14 (0.54) | CA14SSTR4HDAC6HDAC1HDAC2 | |
| SCHEMBL15597263 | 0.87 | CA14 (0.41) | CA14SSTR4HDAC6HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119751354-A | Preparation method and application of functional fatty acid | 铁岭金铎科技股份有限公司 | 2025-04-04 | — | — | CN | disclosed |
| US-20250057944-A1 | OLIGOSACCHARIDE COMPLEXES AND USES | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (ES) | 2025-02-20 | — | — | US | disclosed |
| US-20250057960-A1 | OLIGOSACCHARIDE COMPLEXES AND USES | BioNTech SE (DE) | 2025-02-20 | — | — | US | disclosed |
| US-20240425541-A1 | OLIGOSACCHARIDE COMPOUNDS AND COMPLEXES | BioNTech SE (DE) | 2024-12-26 | — | — | US | disclosed |
| CN-118414171-A | Oligosaccharide complexes and uses | 生物技术公司 | 2024-07-30 | — | — | CN | disclosed |
| CN-118401538-A | Oligosaccharide compounds and complexes | 生物技术公司 | 2024-07-26 | — | — | CN | disclosed |
| EP-4401788-A1 | OLIGOSACCHARIDE COMPLEXES AND USES | BioNTech SE (DE) | 2024-07-24 | — | — | EP | disclosed |
| EP-4402150-A1 | OLIGOSACCHARIDE COMPOUNDS AND COMPLEXES | BioNTech SE (DE) | 2024-07-24 | — | — | EP | disclosed |
| EP-4401789-A1 | OLIGOSACCHARIDE COMPLEXES AND USES | BioNTech SE (DE) | 2024-07-24 | — | — | EP | disclosed |
| EP-4401838-A1 | OLIGOSACCHARIDE COMPOUNDS AND COMPLEXES | BioNTech SE (DE) | 2024-07-24 | — | — | EP | disclosed |
| WO-2007097470-A2 | FUSED NITROGEN- COMPRISING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-08-30 | — | — | WO | disclosed |
| EP-1448195-B1 | N-ADAMANTYLMETHYL DERIVATES AND INTERMEDIATES AS PHARMACEUTICAL COMPOSITIONS AND PROCESSES FOR THEIR PREPARATION | ASTRAZENECA AB (SE) | 2006-11-02 | — | — | EP | disclosed |
| US-7129246-B2 | N-adamantlmethyl derivatives and intermediates as pharmaceutical compositions and processes for their preparation | ASTRAZENECA AB (SE) | 2006-10-31 | — | — | US | disclosed |
| US-20050010052-A1 | N-adamantlmethyl derivatives and intermediates as pharmaceutical compositions and processes for their preparation | ASTRAZENECA AB (SE) | 2005-01-13 | — | — | US | disclosed |
| EP-1448195-A1 | N-ADAMANTYLMETHYL DERIVATES AND INTERMEDIATES AS PHARMACEUTICAL COMPOSITIONS AND PROCESSES FOR THEIR PREPARATION | AstraZeneca AB (SE) | 2004-08-25 | — | — | EP | disclosed |
| US-20030207919-A1 | Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of use | NICOX S.A. (FR) | 2003-11-06 | — | — | US | disclosed |
| US-6593347-B2 | Especially a nitrosated and/or nitrosylated arylpropionic acid, arylacetic acid, enolic anilide or an oxicam | NITROMED, INC. | 2003-07-15 | — | — | US | disclosed |
| WO-2003041707-A1 | N-ADAMANTYLMETHYL DERIVATES AND INTERMEDIATES AS PHARMACEUTICAL COMPOSITIONS AND PROCESSES FOR THEIR PREPARATION | ASTRAZENECA AB (SE) | 2003-05-22 | — | — | WO | disclosed |
| US-20020016322-A1 | Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositons and methods of use | NICOX S.A. (FR) | 2002-02-07 | — | — | US | disclosed |
| US-6297260-B1 | Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of use | NITROMED, INC. | 2001-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016322-A1 | Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositons and methods of use | NOS2, NOS3, NOS1 | CA14 1147/4885SSTR4 1103/4885HDAC6 2282/4885 |
| US-20250057944-A1 | OLIGOSACCHARIDE COMPLEXES AND USES | FUT6, NSUN3, OSTC | CA14 1352/4885SSTR4 2053/4885HDAC6 66/4885 |
| US-20250057960-A1 | OLIGOSACCHARIDE COMPLEXES AND USES | CD4, FUT6, UGCG | CA14 841/4885SSTR4 1182/4885HDAC6 229/4885 |
| US-20240425541-A1 | OLIGOSACCHARIDE COMPOUNDS AND COMPLEXES | OSTC, SNRPA, RNASE1 | CA14 419/4885SSTR4 2902/4885HDAC6 137/4885 |
| US-20050010052-A1 | N-adamantlmethyl derivatives and intermediates as pharmaceutical compositions and processes for their preparation | ADRA1A, ADRA1D, ADORA1 | CA14 3330/4885SSTR4 1235/4885HDAC6 4340/4885 |
| US-20030207919-A1 | Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of use | NOS2, NOS1, NOS3 | CA14 2679/4885SSTR4 2379/4885HDAC6 1956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.